James P. O'Brien

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Craig H. Moskowitz, Stephen D. Nimer, Andrew D. Zelenetz et al. · Blood · 2001 · 427 citations · Full text

Medicine, Oncology, Radiation Oncology +13

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Martin Schlumberger, Barbara Jarząb, Maria E. Cabanillas et al. · Clinical Cancer Research · 2015 · 247 citations · Full text

Medicine, Oncology, Pharmacology +12

Rat dendritic cells function as accessory cells and control the production of a soluble factor required for mitogenic responses of T lymphocytes.

Wolfgang E. F. Klinkert, Jon Henry LaBadie, James P. O'Brien et al. · Proceedings of the National Academy of Sciences · 1980 · 128 citations · Full text

Life Sciences, Cell Biology, Immunology +12

Vertebroplasty in patients with severe vertebral compression fractures: a technical report.

James P. O'Brien, Jon T. Sims, Avery J. Evans · PubMed · 2000 · 117 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +11

A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

Steven I. Sherman, Barbara Jarząb, Maria E. Cabanillas et al. · Journal of Clinical Oncology · 2011 · 99 citations

Medicine, Oncology, Pharmacology +16